For Cancer Patients on Immunotherapy, Harmful Gut Bacteria May Matter More Than Helpful Ones

 Source: Sci Tech Daily, February 2022

Melanoma patients receiving therapy that helps their immune system kill cancer cells respond to treatment differently depending on the types of microbes in their gut, and new research suggests the microorganisms hindering therapy have more influence than the beneficial ones.

Findings by a collaboration that included researchers at Oregon State University, the National Cancer Institute, the Frederick National Laboratory for Cancer Research and the University of Pittsburgh were published today (February 28, 2022) in Nature Medicine.

The research is a key step forward in the fight against multiple types of cancer including melanoma, the most deadly form of skin cancer, said Andrey Morgun of the OSU College of Pharmacy.